Literature DB >> 10091752

The quality of swallowing for patients with operable esophageal carcinoma: a randomized trial comparing surgery with radiotherapy.

R A Badwe1, V Sharma, M S Bhansali, K A Dinshaw, P K Patil, N Dalvi, S G Rayabhattanavar, P B Desai.   

Abstract

BACKGROUND: Surgery is considered the standard treatment for operable esophageal carcinoma, although there is no compelling evidence that surgery can achieve better results than radiotherapy. There has previously been no direct randomized comparison of these two modalities with survival or disease specific outcome end points.
METHODS: Ninety-nine patients with operable squamous cell carcinoma of the esophagus were randomly allocated to surgery or radiotherapy after stratification for tumor length (< or = or >5 cm). Those randomized to surgery underwent transthoracic esophagectomy with limited lymphadenectomy, whereas those in the radiotherapy arm received 50 gray in 28 fractions followed by a 15-gray boost to the primary tumor. Disease specific outcome was assessed for 4 subgroups: 1) disease specific symptoms, 2) physical symptoms, 3) ability to work, and 4) social/family interaction and global perception of disease specific outcome. The questionnaire was given prior to treatment and posttreatment at 3-month intervals for 1 year. Death was a secondary end point.
RESULTS: There was an overall improvement in the quality of swallowing in both treatment arms after treatment and with the passage of time. The swallowing status was better in the surgery arm than in the radiotherapy arm at 6 months after treatment (P = 0.03, Fisher's exact test). Logistic regression analysis showed randomization arm (P = 0.035), time since treatment (P = 0.003), and pretreatment swallowing status to be significant determinants of posttreatment swallowing status. Surgery was twice as likely to result in improvement in swallowing than radiotherapy after correction for time and pretreatment swallowing status. Overall survival was better in the surgery arm than in the radiotherapy arm (P = 0.002, log rank test) (OR = 2.74 with 95% confidence intervals 1.51-4.98; P < 0.009, Cox proportional hazards model).
CONCLUSIONS: Both surgery and radiotherapy can improve the quality of swallowing significantly for patients with operable esophageal carcinoma. Surgery is marginally superior to radiotherapy in improving the quality of swallowing. In this trial, survival in the surgery arm was significantly better than in the radiotherapy arm, although the small number of patients is a limitation.

Entities:  

Mesh:

Year:  1999        PMID: 10091752

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Management of upper gastrointestinal cancers.

Authors:  A Melville; E Morris; D Forman; A Eastwood
Journal:  Qual Health Care       Date:  2001-03

Review 2.  Surgical treatment of esophageal adenocarcinoma: concepts in evolution.

Authors:  Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

3.  Developing countries: an evolving opportunity for oncologic research.

Authors:  Rajendra A Badwe; Anil K D'cruz; Rajesh C Mistry; Hemant B Tongaonkar; Surendra Shastri; Mangesh A Thorat
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 4.  Multimodality approach for locally advanced esophageal cancer.

Authors:  Khaldoun Almhanna; Jonathan R Strosberg
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 5.  Pharmacotherapy for oesophagogastric cancer.

Authors:  Christopher Jackson; Naureen Starling; Yu Jo Chua; David Cunningham
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Non-surgical versus surgical treatment for oesophageal cancer.

Authors:  Lawrence M J Best; Muntzer Mughal; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-03-29

7.  Evaluation of the metabolic response to open and minimally invasive resection of the oesophagus due to oesophageal cancer.

Authors:  Jarosław Pieróg; Michał Bielewicz; Janusz Wójcik; Bartosz Kubisa; Krzysztof Kaseja; Krzysztof Safranow; Barbara Dołęgowska; Piotr Waloszczyk; Tomasz Grodzki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-09-24

Review 8.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.

Authors:  Richard A Malthaner; Rebecca Ks Wong; R Bryan Rumble; Lisa Zuraw
Journal:  BMC Med       Date:  2004-09-24       Impact factor: 8.775

Review 9.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline.

Authors:  Richard A Malthaner; Rebecca K S Wong; R Bryan Rumble; Lisa Zuraw
Journal:  BMC Cancer       Date:  2004-09-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.